03.21.18
WuXi Biologics has selected 4,000 liter Custom Single Run (CSR) disposable bioreactors from ABEC for its new commercial manufacturing facility in Wuxi City, Jiangsu, China. The partnership followed WuXi Biologics' successful testing and evaluation of ABEC's CSR bioreactor technology.
The 4,000L CSR is the largest single-use bioreactor size available in the industry, offering higher productivity and lowering the cost of goods for cell culture-based biopharmaceuticals. The system is designed to perform comparable to stainless steel systems of this scale and can be customized for different products. The 4,000L CSRs will enable manufacturing up to the scale of 24,000L comparable to traditional stainless steel bioreactors.
Dr. Chris Chen, chief executive officer of WuXi Biologics, said, "We are proud to be a global technology leader in bioprocessing and the first company in Asia to advance this exciting new technology. ABEC's large volume single-use bioreactor greatly enhances our commercial manufacturing potential by allowing not only scale-out of capacity but also scale-up. In addition to the flexibility and time to market benefits of single-use manufacturing, we can now offer our clients true economies of scale and address biologics supply needs from kilograms to tons."
"WuXi Biologics' successful testing, evaluation and investment further validates ABEC's CSR technology as one of the most flexible single-use solutions available on the market," said Scott Pickering, ABEC president and chief executive officer. "We are pleased to be part of their next-generation manufacturing strategy and look forward to continuing this long-term partnership."
The 4,000L CSR is the largest single-use bioreactor size available in the industry, offering higher productivity and lowering the cost of goods for cell culture-based biopharmaceuticals. The system is designed to perform comparable to stainless steel systems of this scale and can be customized for different products. The 4,000L CSRs will enable manufacturing up to the scale of 24,000L comparable to traditional stainless steel bioreactors.
Dr. Chris Chen, chief executive officer of WuXi Biologics, said, "We are proud to be a global technology leader in bioprocessing and the first company in Asia to advance this exciting new technology. ABEC's large volume single-use bioreactor greatly enhances our commercial manufacturing potential by allowing not only scale-out of capacity but also scale-up. In addition to the flexibility and time to market benefits of single-use manufacturing, we can now offer our clients true economies of scale and address biologics supply needs from kilograms to tons."
"WuXi Biologics' successful testing, evaluation and investment further validates ABEC's CSR technology as one of the most flexible single-use solutions available on the market," said Scott Pickering, ABEC president and chief executive officer. "We are pleased to be part of their next-generation manufacturing strategy and look forward to continuing this long-term partnership."